AOP Orphan Diseases

Executive Summary

AOP Orphan Diseases (now AOP Health) is an Austrian biopharmaceutical company with a 30-year track record as a European pioneer in rare disease and critical care therapies. The company leverages both biologics and small molecules to address high-unmet medical needs, managing the full product lifecycle from preclinical research through commercialization. Despite its long history, the company remains in the pre-clinical stage, suggesting a continued focus on early-stage innovation and niche indications. Headquartered in Vienna, AOP Health operates with a patient-centric approach, aiming to develop integrated therapies for conditions where few treatment options exist. Its private status and lack of disclosed funding or valuation make it a relatively opaque but potentially high-impact player in the orphan drug space.

Upcoming Catalysts (preview)

• Q2 2027Initiation of Phase 1 trial for lead pipeline candidate40% success
• TBDFDA or EMA orphan drug designation for a novel therapy60% success